NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, RUSSIA, BELARUS OR IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION OR WOULD REQUITE FURTHER REGISTRATION OR OTHER MEASURES ABOVE WHAT IS REQUIRED BY SWEDISH LAW. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.
NB: This is an English convenience translation of this press release. In case of any discrepancy, the correct version is the Swedish original “Stayble Therapeutics AB offentliggör prospect med anledning av företrädesemissionen”.
Today, March 24th, 2023, the subscription period of Stayble Therapeutics AB’s (”Stayble” or ”the Company”) rights issue of shares with preferential right for existing shareholders (“the Rights Issue”). The public is also invited to subscribe for shares. The subscription period lasts up to and including April 12th, 2023. The Rights Issue, if fully subscribed, can provide the Company a maximum of approximately MSEK 35.2, before deduction of transaction related costs. Prospectus and a teaser summary are available at the Company’s (www.staybletherapeutics.com), Sedermera Corporate Finance AB’s (www.sedermera.se) and Nordic Issuing AB’s (www.nordic-issuing.se) respective web pages. The investment documents are also available at Stayble’s web page for the Rights Issue (https://www.foretradesemission.staybletherapeutics.se/).